Medpace Holdings, Inc. [MEDP] Securities Class Action Lawsuit Update

• Case Name: Durbin v. Medpace Holdings Inc., et al.
• Case No.: 1:26-cv-00346-SJD
• Jurisdiction: United States District Court Southern District of Ohio
• Filed on: April 6, 2026
• Class Period: April 22, 2025 and February 9, 2026, inclusive.

Introduction

Medpace Holdings, Inc. (NASDAQ: MEDP), a clinical research organization serving biotech, pharmaceutical, and medical device sponsors, now faces a securities class action after investors alleged the company painted an overly confident picture of its 2025 booking momentum while downplaying a rising cancellation problem embedded in its backlog. According to the complaint, the alleged fraud centers on repeated statements suggesting Medpace could return to roughly 1.15x book-to-bill in the second half of 2025, including Q4, while allegedly understating cancellation risk, even as management allegedly knew cancellation trends and metabolic concentration were affecting pre-backlog visibility and booking expectations.

The alleged truth arrived on February 9, 2026, when Medpace reported a fourth-quarter 2025 book-to-bill ratio of just 1.04x, well below the repeatedly reinforced target. Shares fell from $530.35 to $446.05 the next trading day, wiping out more than 15.9% in market value and triggering this MEDP securities class action.

“Most MEDP shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Medpace operates as a contract research organization, or CRO, managing outsourced clinical trials from Phase I through Phase IV. Its revenue engine depends heavily on backlog conversion and the pace at which new business awards replenish consumed backlog. In this model, book-to-bill is not just a KPI. It is the heartbeat investors use to forecast forward revenue durability.

That made management’s repeated emphasis on a 1.15x second-half 2025 book-to-bill target especially important. Throughout multiple earnings calls, Medpace framed the funding environment as stable to improving, described cancellations as “well behaved,” and suggested that stronger award activity would support accelerating revenue into 2026.

The lawsuit alleges this backdrop mattered because Medpace’s business mix had become increasingly dependent on metabolic studies and a pre-backlog pipeline that offered less visibility than management’s public posture implied. In a CRO model, that concentration can turn quickly when clients delay funding or cancel studies late in the sales funnel. The complaint says that risk was already present.

Promises Made vs. Reality

The core allegation is straightforward: Medpace repeatedly told investors the second half could return to or exceed 1.15x book-to-bill while simultaneously minimizing the significance of cancellations. One of the complaint’s most important quoted statements came in July 2025, when CEO August Troendle told analysts: “We continue to see a strong potential for book-to-bills returning to above 1.15x in Q3.” He paired that with another key reassurance: “Cancellations were down across the pipeline.”

By October, the language became even more confident, with management describing cancellations as “well behaved in Q3, permitting record net bookings and a net book-to-bill of 1.20.” The complaint contrasts those statements with what later emerged: fourth-quarter cancellations spiked again, especially in the metabolic area, driving the ratio down to 1.04x.

Timeline of Alleged Misconduct and Disclosures

April 22, 2025: Medpace first anchors the narrative around improving second-half conditions, with management stating there were “paths toward getting to 1.15.”

July 22, 2025: Management raises confidence, saying cancellations were down and funding conditions had stabilized or improved. The company raises revenue guidance by $280 million at the midpoint.

October 23, 2025: The story peaks. Medpace reports a 1.20x third-quarter ratio, says cancellations remain “well behaved,” and offers a constructive early 2026 growth view.

February 9–10, 2026: The alleged corrective disclosure lands. Medpace reports 1.04x fourth-quarter book-to-bill and admits cancellations were “elevated again in Q4,” the highest in over a year. The stock drops 15.9% in one session.

According to the complaint, that sequence of guidance, reassurance, surprise miss, and stock collapse forms the spine of the MEDP lawsuit narrative.

Investor Harm and Market Reaction

The complaint ties investor harm directly to the February 2026 correction. The one-day decline from $530.35 to $446.05 erased roughly $84.30 per share in value.

Analyst reaction reinforced the loss-causation theory. Baird’s same-day note reportedly warned: “Expect Shares Under Pressure Tomorrow” Its concerns included the Q4 bookings miss, stretched valuation, and slowing 2026 growth relative to the 2021–2025 period.

Truist then cut its price target from $555 to $539, explicitly citing surprise around rising cancellations and weaker-than-expected B2B trends.

The analysts’ reactions are cited in the complaint as part of the theory that the market decline reflected more than a routine quarterly disappointment. The complaint argues the market reaction was not merely to weaker growth, but to the revelation that cancellation risk had been materially understated.

Litigation and Procedural Posture

The action is filed in the U.S. District Court for the Southern District of Ohio as Durbin v. Medpace Holdings Inc., et al., asserting claims under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The named defendants are Medpace, CEO August James Troendle, President Jesse J. Geiger, and CFO Kevin M. Brady.

The proposed class period runs from April 22, 2025 through February 9, 2026.

Scienter allegations focus on repeated precision around the 1.15x target despite alleged access to contrary cancellation data, therapeutic concentration risk, and pre-backlog visibility limits. The complaint emphasizes that the executives themselves discussed cancellations, therapeutic mix, and backlog composition in detail on earnings calls, which the complaint cites as supporting its scienter allegations.

SEC Filings & Risk Factors

The complaint repeatedly cites quarterly earnings releases, public earnings calls, and SEC reporting obligations as the channels through which Medpace allegedly shaped investor expectations.

The lawsuit’s theory is that Medpace failed to adequately communicate:

• the degree to which elevated cancellations persisted beneath headline growth,
• the concentration of weakness in metabolic studies,
• the fragility of pre-backlog conversion assumptions, and
• the risk that 2026 growth models depended on a cancellation environment already becoming unstable.

For CRO investors, this turns routine 10-Q and earnings-call language around backlog quality into the central legal battleground.

How to Join the Medpace (MEDP) Class Action

• Confirm you purchased MEDP shares during the April 22, 2025 to February 9, 2026 period
• Review eligibility details with class counsel
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.